OKYO News and Press, OKYO Pharma Limited From 09/14/23

2023-09-14 10:00:06 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

2023-09-14 09:19:08 ET More on OKYO Pharma Financial information for OKYO Pharma OKYO Pharma rebounds on withdrawal of equity offering For further details see: OKYO Pharma down 4%, withdraws public offering

LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the pric...

2023-09-14 08:35:01 ET Losers: BIOLASE ( BIOL ) -44% on prices $4.5M stock offering . Bionomics Limited ( BNOX ) -20% announces update on the α7 Nicotinic Acetylcholine Receptor positive allosteric modulator collaboration with MSD. Simpple ( SP...

2023-09-13 16:20:01 ET More on OKYO Pharma Seeking Alpha’s Quant Rating on OKYO Pharma Historical earnings data for OKYO Pharma Financial information for OKYO Pharma OKYO Pharma rebounds on withdrawal of equity offering For further details see:...

LONDON and NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced that it ...

2023-09-08 10:00:08 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

2023-09-08 08:45:53 ET Palm Beach, FL – September 8, 2023 – FinancialNewsMedia.com News Commentary – The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome (DES) or Dry E...

2023-09-08 08:27:09 ET Aziyo Biologics ( ELUT ) +19% . Verb Technology Company ( VERB ) +21% . Plus Therapeutics ( PSTV ) +15% Signs CNSid Licensing Agreement with Plus Therapeutics. Bullfrog AI ( BFRG ) +16% Announces Investor Webinar with CEO an...

Full enrollment achieved on September 6 th with a total of 240 patients enrolled in study Top-line data planned for release in December 2023 Phase 2 trial is designed as a potential registration trial, with pre-specified primary efficacy endpoints covering both a sign ...